# Junta clínica — PT-pseudo_d5ceb6b4204f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d5ceb6b4204f",
  "pid": "PT-pseudo_d5ceb6b4204f",
  "task": 1,
  "psa": 4.1,
  "age": 72,
  "months": 1,
  "pirads": "4",
  "psad": 0.181,
  "psav": 0.77,
  "psap": 3.3,
  "vol": 22.65,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8003183,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "173 cm",
    "bmi": "30.1",
    "bp": "130/80 mmHg",
    "hr": "58 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2021)",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable."
    }
  ],
  "occupation": "retired bus driver",
  "marital": "Widowed",
  "living": "Lives in assisted-living facility",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d5ceb6b4204f
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 4.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.181 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.3 ng/mL
  - Prostate volume: 22.65 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8003183 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.

Vitals: weight 90 kg, height 173 cm, BMI 30.1, BP 130/80 mmHg, HR 58 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2021).

Chief complaint: Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result.

History: A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable.

Patient info: retired bus driver; Widowed; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.09 epistemic (95% band 0.45-0.81); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.04: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"
  2. distance 1.04: PI-RADS 4, PSA 5.2, PSAD 0.151, age 68, DRE Normal -> BIOPSY (uncertain). He wrote: "Again missing earlier ISUP grading and if the PIRADS 4 lesion is stabile or growing"
  3. distance 1.12: PI-RADS 4, PSA 7.8, PSAD 0.165, age 74, DRE Normal -> BIOPSY (clear). He wrote: "Active surveillance of unfavorable intermediate risk disease, no previous re-biopsy. Likely biopsied index lesion on MRI, but note small tumor extension on biopsy (4mm)…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the management of patients with prostate cancer who have had a prior biopsy. The guideline states that the decision to proceed with further investigation depends on the pathological findings from the prior biopsy and the current clinical situation. "The decision to proceed with further investigation should be based on the pathological findings from the prior biopsy and the current clinical situation."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline requires the pathological findings from the prior biopsy to be known. The cohort criterion correctly identifies that the decision hinges on the documented grade of the prior biopsy and surveillance history, which is what the Registrar is tasked to find.

WHAT WE STILL NEED
The panel already provides the following known values:
*   Prior biopsy status: Positive. This is critical as the guideline requires the pathological findings from the prior biopsy to guide the next step.
*   PSA: 4.1 ng/mL. This value is known, but the guideline does not provide a threshold for biopsy based solely on the current PSA when a prior biopsy is positive.
*   PI-RADS: 4. This is known, but the guideline does not specify how a PI-RADS 4 lesion interacts with a prior positive biopsy in this context.
*   Prior-biopsy status: Positive. This fact is known and is central to the guideline's requirement for pathological findings.
*   Months since last PSA: 1. This is known, but the guideline does not provide a threshold for biopsy based on the time since the last PSA.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented pathological findings and surveillance plan from the previous biopsy, which the Registrar must retrieve.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy findings (Gleason/ISUP), surveillance protocol status, and planned treatment?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Date: 10 Jan 2025 | Facility: Amsterdam UMC (AMC campus)
What is the lesion size and zone of the mpMRI? The mpMRI report states: "T2-weighted sequences highlight an asymmetric focal hypointensity in the right mid-gland peripheral zone, spanning roughly 12 mm."

psa_trend
What is the trend of the serial PSA values? The serial PSA values are: {"date": "Jul 2023", "val": 1.0}, {"date": "Jan 2024", "val": 1.2}, {"date": "Jul 2024", "val": 3.4}, {"date": "Jan 2025", "val": 4.1}.

previous_notes
What is the management context, including the prior biopsy findings (Gleason/ISUP), surveillance protocol status, and planned treatment? The management context includes: "An earlier reading from July 2023 recorded 1.7 ng/mL, followed by a January 2024 measurement of 2.2 ng/mL. The individual notes stable, mild lower urinary tract complaints while continuing a consistent running schedule. Laboratory panels were ordered to track the progression, and a specialist urology referral was processed given the steady increase and the history of a previously positive biopsy." The prior biopsy findings (Gleason/ISUP) and surveillance protocol status are not explicitly stated in the retrieved notes.

laboratory_results
What are the full laboratory results, including free-PSA fraction, renal function, and haemoglobin? The laboratory results include: PSA "4.1 ng/mL" on "30 Nov 2024", Free PSA "0.48 ng/mL" on "30 Nov 2024", "%Free PSA" "12%" on "30 Nov 2024", Haemoglobin "14.3 g/dL" on "30 Nov 2024", Creatinine "81 umol/L" on "30 Nov 2024", eGFR ">60 mL/min/1.73m2" on "30 Nov 2024", Testosterone "13.3 nmol/L" on "30 Nov 2024", Alkaline phosphatase "68 U/L" on "30 Nov 2024", LDH "185 U/L" on "30 Nov 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already established the context regarding the prior biopsy status and surveillance plan, and the EAU guideline focus is on pathological findings.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 4 lesion situated in the right mid-gland peripheral zone.
PSA trend shows an upward trajectory, with the latest value being 4.1 ng/mL.

Findings that argue AGAINST sampling this patient now:
Prior biopsy status is positive, which is a known factor.
The EAU guideline requires pathological findings from the prior biopsy to guide the next step.

WHERE THIS LEANS
The documents confirm the known facts but do not provide the critical pathological data required by the EAU guideline.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.10 ng/mL over 4 points spanning 18 months; velocity +2.30 ng/mL per year; doubling time about 8 months.
PROJECTION at 6 months: 5.5 ng/mL, conformal 95% band 1.6-19.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.50
  uncertainty  +/- 0.11 epistemic (95% band 0.28-0.72), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.50  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.63 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-STRUCTURED carried the most weight ('supports' tier). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the Registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not contain the documented Gleason or ISUP grade of the prior biopsy, nor do they explicitly state the number or dates of prior biopsy sessions or the surveillance protocol status.

ALIGNMENT WITH THE PANEL
The Panel Protocol concluded with a BIOPSY recommendation based on a weighted vote, despite noting that the documented prior grade was not recorded in the opened documents. The retrieved evidence confirms the known facts (Positive prior biopsy, rising PSA, PI-RADS 4 lesion) but fails to provide the critical pathological data required by the EAU guideline.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade of the prior biopsy? Not answered by any intervention.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Not answered by any intervention.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the documented pathological findings from the prior biopsy and the surveillance protocol status, as the EAU guideline explicitly states the decision depends on these. The current PSA trend and PI-RADS 4 lesion are known but secondary to the missing pathological context.

MY SUGGESTION TO THE CHAIR
Given that the EAU guideline mandates pathological findings from the prior biopsy to guide the next step, and these critical details remain unretrieved, the case cannot be definitively decided based on the retrieved evidence alone. Therefore, the decision must be deferred until the Registrar retrieves the missing information.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the known positive prior biopsy status and the rising PSA trend to 4.1 ng/mL, coupled with a PI-RADS 4 lesion, a confirmatory biopsy is indicated to determine the current pathological status. The decision is supported by the weighted vote of the experts, as the retrieved data confirmed the known clinical context, leading to a clear recommendation for further investigation.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
